Wright Medical Group NV overcame vendor quality challenges to gain FDA approval for its biologic-based Augment bone graft for aiding ankle/hindfoot fusion surgeries, opening up a $300 million U.S. market opportunity. The firm announced the approval Sept. 1. It's the first indication for a product platform that Wright hopes to extend to soft-tissue markets with even bigger potential.
The Augment platform combines tricalcium phosphate granules and recombinant human platelet-derived growth factor (rhPDGF) to stimulate healing following fusion